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Background
• A 54 y/o female with severe PAH, WHO group 1, 
NYHA class III. 
•Tx: 
– PDE-5 
–type-A selective endothelin receptor antagonist,
–IV Epoprostenol x 4 yrs
•S/E: 
–flushing
–sinus congestion
–GI upset, generalized edema
–shortness of breath
–headaches 
•C/O: 
–central catheter discomfort
–depression
–poor quality of life
Purpose
Implications for Practice
• Historically IV prostacyclins were the only 
treatment option indicated for the pulmonary 
hypertension (PH) patient population. 
• Central lines carry risks for infection, sepsis, line 
fractures, and pain at the insertion site which are 
associated with patient’s reporting a reduced 
quality of life.
• Oral prostacyclins offer an optimal treatment plan 
with improved quality of life.
• There is a lack of clinical trials to support the 
transition from IV to oral therapies.
• This case study details the transition from an IV 
Epoprostenol to oral Treprostinil over a seven 
week period.
• Patients meeting certain criteria can safely be 
transitioned from IV to oral prostacylins.  
• Reduction of infection due to central line 
removal.
• Reduced risk of abrupt discontinuation of 
treatment due to central line/pump malfunction. 
• Improved quality of life 
• Delivering more cost effective care by reducing 
the need for pump maintenance
Contact Information
• The patient was successfully transitioned from IV 
to oral therapy with no adverse events or 
functional decline. 
• The patient reported having an improved quality 
of life and was able to resume swimming and 
other hobbies that had been contraindicated 
when IV therapy was initiated. 
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Medication Prostacyclin Total Epoprostenol
Week 1 
(05/23/2016) Dose: 0.125mg po TID
(use 1 tab of 0.125mg TID/daily) 0.375mg/day 18ng/kg/min
Week 2
(05/30/2016) Dose: 0.5mg po TID 
(use 2  tabs  of 0.25mg TID for a total 
of  6 tabs/daily)
1.5mg/day 14ng/kg/min
Week 3 
(06/06/2016) Dose : 1mg po TID
(use  4 tabs of 0.25mg TID for a total  
12 tabs/daily)
3mg/day 10ng/kg/min
Week 4 
06/13/2016) Dose: 2mg po TID 
(use 2  tablets of  1mg TID for a total 
of 6 tabs/daily)
6mg/day 6ng/kg/min
Week 5 
(06/20/2016) Dose: 
morning 3.5mg (use 2.5mg tab + 
1mg tab) 
noon 3.0mg (use 2.5mg tab + 0.5mg 
tab) 
evening 3.5mg (use 2.5mg + 1mg 
tab) 
10mg/day 3 ng/kg/min
Week 6
(06/27/2016) Dose:
morning 4mg (use 2.5mg tab + 1mg 
tab + 0.25tab + 0.25mg tab) 
noon 4mg (use 2.5mg tab + 1mg tab 
+ 0.25mg tab + 0.25mg tab)  
evening 4.5mg (use  2.5mg tab +     
2 tabs of 1mg)
12.5mg/day 1.5ng/kg/min
Week 7
(07/04/2016) Dose:
morning 4mg (use 2.5mg tab + 
1mg tab + 2 tablets of 0.25mg) 
noon 5mg (use 2 tabs of 2.5mg) 
evening 5mg (use 2 tabs of 2.5mg)
14mg/day Stop infusion
Improved Quality of Life!
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Case Description
Results
Transition Schedule Table Methods
• A  comprehensive plan of care was developed by 
a multidisciplinary healthcare team.
• Weekly transitions were closely monitored by the 
cardiologist and the Outpatient Pulmonary 
Hypertension Clinic staff. 
• The patient’s mental and physical well being was 
evaluated and documented during the seven 
week period.
